Menarini set to acquire Stemline for $677m
Menarini adds Stemline’s lead product, Elzonris, and its presence in the US with buyout deal.
Archives for May 7, 2020
Alexion in $1.4bn buyout for reversal agent
Alexion agrees deal for Portola to gain access to its lead product, Andexxa, a treatment that counteracts anticoagulants.